Drug Type AAV based gene therapy |
Synonyms recombinant adeno-associated virus 5 vector expressing a functional human cyclic nucleotide gated channel subunit beta 1 (CNGB1) gene (NIH/NCATS) |
Target |
Mechanism CNGB1 modulators(cyclic nucleotide gated channel subunit beta 1 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Retinitis Pigmentosa | Preclinical | US | 23 Sep 2024 | |
Retinitis Pigmentosa | Preclinical | US | 23 Sep 2024 |